BIOGGIO, SWITZERLAND: In a move that reshapes the global marine lipids industry, KD Pharma Group has finalized the acquisition of dsm-firmenich’s marine lipids business, positioning itself as the world’s largest omega-3 manufacturer.
The deal, initially announced in July and officially closed on October 1, 2024, marks a significant milestone in the pharmaceutical and nutraceutical sectors. The transaction includes dsm-firmenich’s omega-3 fish oil operations serving the food and beverage, dietary supplement, and pharmaceutical markets.
It also transfers the well-known MEG-3 brand and state-of-the-art production facilities located locally in Mulgrave and in Piura, Peru, into KD Pharma’s portfolio.
In exchange, dsm-firmenich has acquired a minority stake in the expanded KD Pharma Group, signaling a collaborative approach to long-term growth in the lipids space.
“This is a historic day for our company,” CEO of KD Pharma Group Oscar Groet said announcing the acquistion. “We now have a leadership position throughout the value chain – from refined oils to pharmaceutical APIs to softgel capsule manufacturing. This acquisition strengthens our ability to deliver innovative health solutions that help people live better lives.”
The acquisition increases KD Pharma Group’s manufacturing footprint to seven facilities across the UK, Norway, Germany, Canada, Peru, and the U.S., employing approximately 710 people worldwide. It also allows the company to expand its product offering and customization capabilities, creating new opportunities for clients and partners alike.
Importantly, the MEG-3 brand will remain a staple in dsm-firmenich’s portfolio for the Early Life Nutrition market and in its powder product line. As dsm-firmenich, is a global leader in health, nutrition, and beauty, they will continue to focus on innovation in adjacent categories while maintaining a strategic interest in the newly enlarged KD Pharma Group.
“This transaction aligns perfectly with our strategic vision of being technology leaders in lipids,” Groet added. “And [it] enhances our ability to innovate and deliver exceptional value to our customers.”
For Mulgrave, where the recently acquired marine lipid plant operates – the acquisition brings the promise of continued industrial activity and job security within a rapidly growing global market.